Answers are grounded in this paper and cite their sources.
Adding magnetite (mixed iron(II) and iron(III) oxide) to sonodynamic cancer treatment protocols reportedly enhances cytotoxic effects both in vitro and in vivo. However, the underlying mechanisms, especially those related to the release of Fe(II) and to Fenton chemistry, are poorly understood. Using a combined cell culture and chemical approach, we explore some of these mechanisms and their likely biological significance. We apply an in vitro model of sonodynamic treatment utilizing magnetosomes (bacterially derived magnetite nanoparticles). Magnetosomes alone, while showing similar uptake and subcellular distribution, show toxicity toward sarcoid cells but not toward their non‐neoplastic parental cells. Concomitant low‐intensity ultrasound treatment of the cells under strict avoidance of hyperthermia does not increase toxicity despite generating hydroxyl radical‐associated markers in both cell types. Chemical experiments reveal that Fe(II) is released from magnetosomes by ion exchange against other bivalent cations, rather than by dissolution, which is the commonly perceived mechanism. Hypoxia increases the reaction yield, while sonication accelerates its kinetics. We conclude that ion exchange as the main modality of iron release is a pivotal determinant of Fenton chemistry in sonodynamic therapy protocols with magnetite nanoparticles. This critical aspect, especially related to the timing of ultrasound application, should be given the utmost consideration.
No takes yet. Share an insight, caveat, or question.
Dahlmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: